Overview

The inside story of the race to develop Ozempic – the world’s first truly effective and safe obesity drug – and its potentially revolutionary effects on public health, and our deeper culture and values. 'ENLIGHTENING' Publishers Weekly A ‘cure’ for obesity has long evaded the pharmaceutical industry, until the development of Ozempic: a diabetes medication that targets the GLP-1 hormone and makes people feel fuller for longer. After decades of research, Ozempic’s creator Novo Nordisk quickly became one of the most valuable companies in Europe. Now it struggles to keep up with its rivals in an explosive and lucrative market for weight-loss injections. The treatment is so effective that it’s already disrupted industries from healthcare to fast food to fashion. Financial investment has skyrocketed and public demand continues to soar alongside celebrity endorsements. Beyond million-dollar profits, countless lives could now be saved from preventable diseases, but one question remains: are these drugs too good to be true? Through original reporting and rigorous research, Aimee Donnellan uncovers the complicated history of a medical breakthrough that is changing the world, while raising difficult questions about inequality, morality, our beauty ideals and the pursuit of thinness. Along the way, Donnellan profiles the female scientist whose contributions to the discovery of GLP-1 were overlooked and some of the earliest Ozempic users share powerful testimonies. Off the Scales is a revelatory, gripping and urgent study of the unexpected consequences of finally getting what we’ve wanted for so long. 'The definitive account of a singular global force – essential reading to help us understand what has been unleashed and what may be coming next' Andy Slavitt, author of Preventable 'A riveting and impeccably researched deep-dive into the murky world of drug development' Josie Cox, author of Women Money Power 'Donnellan captures the drama behind the science … and explores the wider implications for society, health and business in this deeply researched book' John Collingridge, Guardian business editor

Full Product Details

9780008719081

Table of Contents

Reviews

'Donnellan chronicles the search for miracles, the ensuing gold rush, the lives impacted, the biases overturned and solidified, and where this paradigm shift will leave us. Off the Scales is the definitive account of a singular global force – essential reading to help us understand what has been unleashed and what may be coming next' Andy Slavitt, author of Preventable 'Ultimately, the book presents a scathing critique of the big corporations that have shamelessly leveraged people’s insecurities to get rich, and offers a mixed prognosis for the future: Ozempic may hold a world of promise, but there could be a far darker side that we’re only just starting to see' Josie Cox, author of Women Money Power 'Off the Scales captures the many facets of this fast-moving story, including the decades of scientific research that led to their creation, the stories of early patients and the culture change required to understand obesity as a medical condition rather than a character flaw. Donnellan is a gifted storyteller who brings complicated subjects to life and offers a hopeful vision for how these therapies are transforming lives and reshaping our approach to health care' Leana Wen, M.D., author of Lifelines 'A riveting read about one of the most important medical advances of our time. Aimee Donnellan captures the drama behind the science, the cast of characters who devoted their lives to it, the cutthroat world of drug development and explores the wider implications for society, health and business in this deeply researched book' John Collingridge, Guardian business editor '[An] enlightening debut history of Ozempic and its societal impact … Donnellan cogently sizes up its future potential: GLP-1 could lead to a healthier population empowered to demand healthier foods and living conditions, or it could further expand the gulf between rich and poor. It makes for an astute, fairminded primer on the drug’ Publishers Weekly

'Donnellan chronicles the search for miracles, the ensuing gold rush, the lives impacted, the biases overturned and solidified, and where this paradigm shift will leave us. Off the Scales is the definitive account of a singular global force—essential reading to help us understand what has been unleashed and what may be coming next' Andy Slavitt, author of Preventable 'Donnellan provides a riveting and impeccably researched deep-dive into the murky world of drug development and casts a light on the little-known characters who have dedicated their lives to rewriting the rules of science … Ultimately, the book presents a scathing critique of the big corporations that have shamelessly leveraged people’s insecurities to get rich, and offers a mixed prognosis for the future: Ozempic may hold a world of promise, but there could be a far darker side that we’re only just starting to see' Josie Cox, journalist and author of Women, Money, Power 'Ozempic and the other GLP-1 medications are among the most important medical breakthroughs of our time. Off the Scales captures the many facets of this fast-moving story, including the decades of scientific research that led to their creation, the stories of early patients and the culture change required to understand obesity as a medical condition rather than a character flaw. Donnellan is a gifted storyteller who brings complicated subjects to life and offers a hopeful vision for how these therapies are transforming lives and reshaping our approach to health care' Leana Wen, M.D., Washington Post contributing columnist and author of Lifelines

Author Information

Aimee Donnellan has been a columnist at Reuters for six years, where she has closely followed Big Pharma (among many other topics). Previously she was banking correspondent at the Sunday Times (London). She has been a journalist for over 15 years and started her career investigating the opaque worlds of hedge funds and online gambling. She also covered the bond market after the 2008 financial crash for the investment bankers' bible, International Financing Review. Aimee grew up in Galway in the west coast of Ireland and lives in London with her wife and two children. Off the Scale is her first book.

Tab Content 6

Countries Available